A 52-year-old man with stable COPD presents with persistent dyspnea despite using a short-acting beta-2 agonist (SABA) as needed. He has no features of acute exacerbation. Which drug is the first-line choice for maintenance therapy in this patient?

Explanation

## First-Line Maintenance Therapy in Stable COPD **Key Point:** Long-acting anticholinergics (LACs) like tiotropium are the preferred first-line maintenance agents for stable COPD with persistent symptoms despite SABA use. ### Rationale for Tiotropium **High-Yield:** Tiotropium is a long-acting muscarinic antagonist (LAMA) with the following advantages: 1. **Duration:** 24-hour effect — once-daily dosing improves adherence 2. **Mechanism:** Blocks M3 receptors on airway smooth muscle, producing sustained bronchodilation 3. **Evidence base:** GOLD guidelines (2023) recommend LACs or LABAs as first-line maintenance in symptomatic COPD 4. **Safety:** Well-tolerated with minimal systemic absorption via inhalation ### Comparison of Maintenance Agents | Agent | Class | Duration | Onset | First-Line? | |-------|-------|----------|-------|-------------| | **Tiotropium** | LAMA | 24 h | 30 min | **Yes** | | Formoterol | LABA | 12 h | 1–3 min | Yes (alternative) | | Ipratropium | SAMA | 4–6 h | 15 min | No (short-acting) | | Theophylline | Methylxanthine | 8–12 h | 30 min | No (third-line) | **Clinical Pearl:** Although formoterol (LABA) is also acceptable as first-line, tiotropium is preferred in many guidelines because anticholinergics do not increase cardiovascular risk (unlike LABAs in some patient subsets) and provide superior symptom control in COPD-predominant disease. **Mnemonic:** **LAMA-LABA-ICS** — the stepwise escalation in COPD: start with Long-Acting Muscarinic Antagonist or Long-Acting Beta-Agonist, add Inhaled CorticoSteroid if exacerbations occur. [cite:KD Tripathi 8e Ch 16]